Singapore's ImpacFat launches in Tokyo with cultivated fish fat and a skincare first strategy

Fish cells bring a Singapore venture to Tokyo

Singapore startup ImpacFat launched operations in Japan on October 1, 2025, opening a new base for its effort to grow fish fat from cells rather than harvest it from the ocean. The company says it is the first in the world to cultivate fish fat rich in Omega 3 from fish stem cells, with potential uses stretching from skincare to future cultivated sashimi.

The Tokyo operation includes a shared office and laboratory at Link Scholar's Hub in Takanawa Gateway City, secured through a service contract with East Japan Railway Company, or JR East. The move puts Singapore research inside a Japanese innovation district, close to a market with a deep seafood tradition, strong demand for supplements and exacting expectations for food quality.

ImpacFat wants its ingredient to improve the taste, texture, aroma and nutrition of alternative proteins. Its immediate commercial route, however, is cosmetics and skincare, where the rules are clearer than those governing cultivated seafood. The company is targeting approvals for use in Singapore and Japan by March 2026, while food applications remain a longer range ambition.

The expansion also brings Japanese industrial backing. Toyo Seikan Group has invested in the business, alongside other investors with links to scientific development and biological manufacturing. ImpacFat plans to keep its research core in Singapore while building a small team in Japan to develop products and work with local partners.

Why the company is starting with fat

Fat shapes much of what people recognise in a mouthful of seafood. It carries flavour compounds, contributes softness or silkiness, and affects how food cooks and releases aromas. Its melting and sizzling also help create the sensory experience people associate with fish and meat.

Many products made from plants use coconut or seed oils to supply those qualities. Those oils behave differently from animal fat, however, and can lose taste or aroma after cooking. ImpacFat aims to recreate the structure and lipid profile of fish fat tissue, supplying some of the qualities that alternative seafood can lack.

The company's proposed role is largely that of an ingredient supplier. Cultivated fish fat could be blended with proteins from soy, pea or algae to improve seafood made from plants. It could also be combined with cultivated fish muscle to produce cuts that more closely resemble conventional seafood.

ImpacFat also sees possibilities beyond improving existing alternatives, including future sashimi grown from cells. That ambition connects its work on an ingredient to the larger challenge of recreating seafood's appearance, texture and eating experience without fishing.

How fish cells become a usable ingredient

ImpacFat's process begins with cells sourced from fish species. The cells are multiplied in sterile tanks called bioreactors, then guided under specific conditions to become adipocytes. These are the cells that store lipids, the fats and related substances found in living tissue.

The adipocytes gradually accumulate droplets of fat. The resulting fatty tissue can then be harvested for use as an ingredient. The approach draws on advances in stem cell biology and tissue culture that have progressed quickly over the past decade.

Fat can be simpler to cultivate at scale than whole muscle because it does not need complex fibres or layered structures to perform its basic role. Producers still need secure cell lines, reliable growth media and control over the cost of large production runs. Growth media are the mixtures that supply cells with the materials they need to grow.

Many cultivated protein companies are working toward media without animal components and growth factors derived from plants. Growth factors provide signals that influence cell development. Bringing these supplies closer to commodity prices would help move cultivated ingredients toward costs suitable for wider markets.

ImpacFat has begun bringing components and methods into its own operations to reduce costs. It also plans joint research with partners in Japan on more efficient ways to grow and harvest fat. Stable cell lines, cheaper media and greater output from bioreactors will all matter to its ambition of matching conventional prices.

Omega 3, nutrition and contamination claims

Fish fat is valued partly for its Omega 3 fatty acids, particularly EPA and DHA. Humans do not make these efficiently, so diet is an important source, often through fish or fish oil supplements. Studies have linked Omega 3 intake with heart health, brain function, blood pressure regulation and vision.

ImpacFat says its cultivated fat can deliver these beneficial fats while avoiding contaminants sometimes found in marine ingredients. According to the company, controlled growing conditions produce fat free from mercury, microplastics and common pathogens. Heavy metals and other contaminants can accumulate in wild fisheries.

Fish cells can produce lipids that resemble the fatty acid profile associated with seafood. ImpacFat says it can adjust the composition toward EPA and DHA targets, depending on the fish species and the conditions used to grow the cells. That control is part of its pitch to manufacturers seeking consistent ingredients.

Food applications will require approval in each market, including checks that production meets safety and quality standards. The company is therefore pursuing skincare while preparing for later food uses. Its proposed commercial advantages include precise fatty acid levels and ingredients made without marine contaminants.

Japan offers demand, partners and supply concerns

Japan combines strong awareness of Omega 3 with substantial markets for seafood and supplements. Its consumers place a high value on marine nutrition, taste and quality, making it both a promising destination and a demanding place to introduce a new seafood ingredient.

The country also faces food security pressures. Japan's food self sufficiency rate has hovered around 38 percent in recent years. Imported fish supplies can fluctuate as climate change, overfishing and geopolitical restrictions affect catches and prices.

Takanawa Gateway City gives ImpacFat a base within an innovation district backed by JR East. The location offers laboratory space and access to potential partners in food processing, distribution and biotechnology. The company believes those connections can speed development and validation.

ImpacFat has about 10 people in Singapore and plans to add up to three in Japan. The Tokyo operation is intended to complement Singapore research rather than replace it. Local work could help the company adapt formulations to Japanese preferences and validate quality with partners while retaining its core platform in Singapore.

The sequence of the expansion and the next target date is straightforward:

• October 1, 2025: ImpacFat launched its Japanese operation, with shared office and laboratory space at Link Scholar's Hub in Tokyo.
• October 2, 2025: The company is pursuing cosmetics and skincare as its initial commercial route while developing broader applications.
• March 2026: ImpacFat targets approvals for use of its cultivated fish fat in Singapore and Japan.

Skincare comes before the food market

Japan does not yet have a fully defined route for approving cultivated meat or seafood for sale as food. Government agencies and industry groups have begun working toward guidelines. Singapore has moved earlier on cultivated protein approvals, although each new product and production process still requires a separate review.

ImpacFat sees cosmetics and skincare as a faster route to market because the rules are clearer. Its near term plans also include beauty products and supplements, followed by premium pet nutrition. Fish lipids are already common in these categories, giving the company potential applications beyond alternative seafood.

Possible skincare formulations include products for skin barrier support, moisturisation and wound recovery, areas where lipids help protect and repair tissue. The company's proposed early skincare uses sit in the cosmetics category rather than food, lowering the initial barrier as production expands.

Food remains the longer range goal, dependent on regulatory clearance, finalised standards and evidence of safety at commercial scale. No date has been given for food approval or the sale of cultivated sashimi. The March 2026 target concerns the company's initial approvals for use in Singapore and Japan.

Singapore research meets Japanese industrial experience

ImpacFat emerged from Singapore's deep technology ecosystem, with links to A STAR, Republic Polytechnic and the National University of Singapore. Its cofounders include chief executive Mandy Hon and stem cell biologist Dr Shigeki Sugii, a principal investigator at A STAR.

Sugii has spent two decades publishing research on fat biology, stem cells and metabolic health. The company holds patents covering key markets including Singapore, Japan, China, Europe and the United States. Its Japanese expansion builds on that scientific and intellectual property base.

Toyo Seikan Group brings a different kind of experience. Founded in 1917, the Japanese packaging and materials company helped pioneer the retort pouch in 1968, a breakthrough in packaging for ready meals that combined food safety with a long shelf life.

The group now operates across packaging, engineering, functional materials and logistics, with a large global footprint. Its knowledge of process engineering, quality systems and commercialisation could help ImpacFat move from laboratory methods toward industrial production standards.

Other backers include 144 Ventures, part of Leave a Nest Group, and Lin Xiangliang, chief executive of bioprocess company Esco Aster. That investor mix could provide access to pilot manufacturing, validation partners and distribution networks.

JR East's service contract adds a physical base to those financial and industrial relationships. Together, the Tokyo location, investment and partner network give ImpacFat places to test products, engage regulators and refine formulations for different uses.

What the environmental estimates involve

ImpacFat presents cultivated fish fat as an alternative to fish oil and the fishing activities that supply marine lipids. The company estimates that producing one tonne of its cultivated fat could spare up to 3,000 marine lives, depending on the species and assumptions about yield.

The startup also projects greenhouse gas emissions up to 80 percent lower than those associated with conventional fish oil production. Both figures are company estimates, with the animal welfare calculation tied to how much fat different marine species yield.

Conventional marine oil production can involve fuel burned by vessels travelling to fishing grounds, nets that catch mixed species, processing plants that refine oil, and shipment to buyers. Cultivating fat in urban tanks shifts more of the production footprint toward electricity and materials, which can increasingly come from sources with low carbon emissions.

ImpacFat's approach also aims to reduce pressure on wild fish stocks affected by overfishing and habitat loss. Japan's culinary and cultural ties to species such as tuna and eel make sustainable sourcing a complex challenge.

Replacing a portion of marine lipids with cultivated fat could diversify supply, improve resilience and reduce bycatch associated with industrial fishing. Bycatch refers to marine animals caught alongside the intended catch. Cultivated ingredients would address part of the demand for marine fats while fisheries continue to face wider pressures.

A specialised place in a growing market

ImpacFat is entering a market that already has alternatives to conventional fish oil. Oils derived from algae can provide EPA and DHA without fishing. Other companies are developing cultivated fat from land animals, with food applications focused on pork or beef fat.

The Singapore startup's focus is fish fat grown from fish cells. That gives it a distinct target: an ingredient combining the taste profile of seafood with marine nutrition, for use across food, beauty products and pet care.

Analysts forecast that the global Omega 3 ingredients market will exceed $8 billion by 2030. Cultivated sources could capture part of that growth if companies can align production scale, cost and regulatory approval. ImpacFat's challenge is to turn laboratory control into consistent quality at progressively lower prices.

Japan provides a demanding commercial test because it combines research depth, manufacturing discipline and consumers with strong expectations for seafood. Success there could help validate cultivated fish fat for other markets, including the United States and Europe, where regulators are also developing rules for foods grown from cells.

For ImpacFat, the next practical steps are to build its Japanese team, work with local research and industrial partners, reduce production costs and pursue its March 2026 approval target. Skincare offers the first proposed outlet, while food applications depend on a longer programme of development and regulatory review.

Key Points

• ImpacFat launched in Japan on October 1, 2025, with a shared laboratory and office at Link Scholar's Hub in Takanawa Gateway City.
• The Singapore startup says it is the first company to cultivate fish fat rich in Omega 3 from fish stem cells.
• Cosmetics and skincare are its initial commercial focus, with approvals targeted in Singapore and Japan by March 2026.
• Longer range plans include supplements, premium pet nutrition, ingredients for alternative seafood and cultivated sashimi.
• Japan has no fully defined approval route for cultivated meat or seafood, and no food launch date has been given.
• Investors include Toyo Seikan Group, 144 Ventures and Esco Aster chief executive Lin Xiangliang.
• The company has about 10 staff in Singapore and plans to add up to three in Japan.
• ImpacFat estimates up to 80 percent lower greenhouse gas emissions than conventional fish oil production and up to 3,000 marine lives spared per tonne of cultivated fat.
• The global Omega 3 ingredients market is forecast to exceed $8 billion by 2030.